CONCORDBIO — Concord Biotech Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual income statement for Concord Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	7,129	8,532	10,169	12,001	10,549
Cost of Revenue
Gross Profit	4,773	5,753	6,828	7,823	6,930
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	4,893	5,621	6,389	7,452	7,617
Operating Profit	2,236	2,911	3,780	4,549	2,931
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	2,375	3,220	4,126	4,946	3,446
Provision for Income Taxes
Net Income After Taxes	1,749	2,401	3,081	3,716	2,592
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,749	2,401	3,081	3,716	2,609
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,749	2,401	3,081	3,716	2,609
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	16.7	23	29.4	35.5	25.2
Dividends per Share